164 related articles for article (PubMed ID: 15827204)
21. Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells.
Iwata S; Saito T; Ito Y; Kamakura M; Gotoh K; Kawada J; Nishiyama Y; Kimura H
Cancer Sci; 2012 Feb; 103(2):375-81. PubMed ID: 22017376
[TBL] [Abstract][Full Text] [Related]
22. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
Leong IT; Fernandes BJ; Mock D
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
[TBL] [Abstract][Full Text] [Related]
23. Lytic induction and apoptosis of Epstein-Barr virus-associated gastric cancer cell line with epigenetic modifiers and ganciclovir.
Jung EJ; Lee YM; Lee BL; Chang MS; Kim WH
Cancer Lett; 2007 Mar; 247(1):77-83. PubMed ID: 16647201
[TBL] [Abstract][Full Text] [Related]
24. Aspirin induces lytic cytotoxicity in Epstein-Barr virus-positive cells.
Liu SF; Wang H; Li ZJ; Deng XY; Xiang H; Tao YG; Li W; Tang M; Cao Y
Eur J Pharmacol; 2008 Jul; 589(1-3):8-13. PubMed ID: 18571159
[TBL] [Abstract][Full Text] [Related]
25. Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
Ladell K; Dorner M; Zauner L; Berger C; Zucol F; Bernasconi M; Niggli FK; Speck RF; Nadal D
Cell Microbiol; 2007 Aug; 9(8):2055-69. PubMed ID: 17419714
[TBL] [Abstract][Full Text] [Related]
26. Interfering with cellular signaling pathways enhances sensitization to combined sodium butyrate and GCV treatment in EBV-positive tumor cells.
He Y; Cai S; Zhang G; Li X; Pan L; Du J
Virus Res; 2008 Jul; 135(1):175-80. PubMed ID: 18455826
[TBL] [Abstract][Full Text] [Related]
27. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.
Worth A; Conyers R; Cohen J; Jagani M; Chiesa R; Rao K; Goulden N; Veys P; Amrolia PJ
Br J Haematol; 2011 Nov; 155(3):377-85. PubMed ID: 21910716
[TBL] [Abstract][Full Text] [Related]
28. Tumor outgrowth in peripheral blood mononuclear cell-injected SCID mice is not associated with early Epstein-Barr virus reactivation.
Piovan E; Bonaldi L; Indraccolo S; Tosello V; Menin C; Comacchio F; Chieco-Bianchi L; Amadori A
Leukemia; 2003 Aug; 17(8):1643-9. PubMed ID: 12886254
[TBL] [Abstract][Full Text] [Related]
29. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.
Carpenter B; Haque T; Dimopoulou M; Atkinson C; Roughton M; Grace S; Denovan S; Fielding A; Kottaridis PD; Griffiths P; Mackinnon S; Emery V; Chakraverty R
Transplantation; 2010 Sep; 90(5):564-70. PubMed ID: 20555307
[TBL] [Abstract][Full Text] [Related]
30. Parthenolide induces apoptosis and lytic cytotoxicity in Epstein-Barr virus-positive Burkitt lymphoma.
Li Y; Zhang Y; Fu M; Yao Q; Zhuo H; Lu Q; Niu X; Zhang P; Pei Y; Zhang K
Mol Med Rep; 2012 Sep; 6(3):477-82. PubMed ID: 22735892
[TBL] [Abstract][Full Text] [Related]
31. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues.
Moore SM; Cannon JS; Tanhehco YC; Hamzeh FM; Ambinder RF
Antimicrob Agents Chemother; 2001 Jul; 45(7):2082-91. PubMed ID: 11408227
[TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr virus infections: prospects for treatment.
Gershburg E; Pagano JS
J Antimicrob Chemother; 2005 Aug; 56(2):277-81. PubMed ID: 16006448
[TBL] [Abstract][Full Text] [Related]
33. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis.
Balamuth NJ; Nichols KE; Paessler M; Teachey DT
J Pediatr Hematol Oncol; 2007 Aug; 29(8):569-73. PubMed ID: 17762500
[TBL] [Abstract][Full Text] [Related]
34. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.
Clave E; Agbalika F; Bajzik V; Peffault de Latour R; Trillard M; Rabian C; Scieux C; Devergie A; Socié G; Ribaud P; Adès L; Ferry C; Gluckman E; Charron D; Esperou H; Toubert A; Moins-Teisserenc H
Transplantation; 2004 Jan; 77(1):76-84. PubMed ID: 14724439
[TBL] [Abstract][Full Text] [Related]
36. Ganciclovir augments the lytic induction and apoptosis induced by chemotherapeutic agents in an Epstein-Barr virus-infected gastric carcinoma cell line.
Ji Jung E; Mie Lee Y; Lan Lee B; Soo Chang M; Ho Kim W
Anticancer Drugs; 2007 Jan; 18(1):79-85. PubMed ID: 17159505
[TBL] [Abstract][Full Text] [Related]
37. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
Coppoletta S; Tedone E; Galano B; Soracco M; Raiola AM; Lamparelli T; Gualandi F; Bregante S; Ibatici A; di Grazia C; Dominietto A; Varaldo R; Bruno B; Frassoni F; Van Lint MT; Bacigalupo A
Biol Blood Marrow Transplant; 2011 Jun; 17(6):901-7. PubMed ID: 20950702
[TBL] [Abstract][Full Text] [Related]
38. Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model.
Novalić Z; Verkuijlen SAWM; Verlaan M; Eersels JLH; de Greeuw I; Molthoff CFM; Middeldorp JM; Greijer AE
J Med Virol; 2017 Dec; 89(12):2207-2216. PubMed ID: 28853217
[TBL] [Abstract][Full Text] [Related]
39. Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone.
Dugan JP; Haverkos BM; Villagomez L; Martin LK; Lustberg M; Patton J; Martin M; Huang Y; Nuovo G; Yan F; Cavaliere R; Fingeroth J; Kenney SC; Ambinder RF; Lozanski G; Porcu P; Caligiuri MA; Baiocchi RA
Clin Cancer Res; 2018 Jul; 24(14):3273-3281. PubMed ID: 29632007
[No Abstract] [Full Text] [Related]
40. Latent and lytic Epstein-Barr virus replication strategies.
Tsurumi T; Fujita M; Kudoh A
Rev Med Virol; 2005; 15(1):3-15. PubMed ID: 15386591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
